Futibatinib
VIDEO: Strategic sequencing of targeted therapies key in cholangiocarcinoma
In this video, Lionel Aurelien Kankeu Fonkoua, MD, discusses the impact of sequencing targeted therapies when treating patients with cholangiocarcinoma.
Futibatinib confers benefit in FGFR-altered intrahepatic cholangiocarcinoma
Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to results of a phase 2 study.
VIDEO: Emergence of targeted therapies ‘broadened treatment options’ for cholangiocarcinoma
In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.
FDA approves futibatinib for cholangiocarcinoma
The FDA granted accelerated approval to futibatinib for certain patients with cholangiocarcinoma.
FDA grants priority review to futibatinib for advanced cholangiocarcinoma
The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma.
FDA grants breakthrough therapy status to futibatinib for advanced cholangiocarcinoma
The FDA granted breakthrough therapy designation to futibatinib for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 gene rearrangements, according to a press release from the agent’s manufacturer.